Jun 22, 2022 · To validate our findings, we ablated the BAF component SMARCD2 or the cBAF-specific component ARID1A using CRISPR editing in OT-I cells. After adoptive transfer, we challenged the recipient mice...

Dec 12, 2019 · In this study, we showed that Arid1a conditional knockout mice had a high incidence of SCCs occurring in the tongue and esophagus. ARID1A depletion promoted tumor initiation and cancer stemness in human SCC cells.

The mRNA levels of MYC, a known oncogene, were significantly higher in the ARID1A mutation group compared to the WT ARID1A group (p=9.28 e−8, q=1.332 e−4; Fig. 2D). In summary, these human clinical results revealed that an ARID1A mutation was associated with poorer prognosis in …

ARID1A, a member of the SWI/SNF chromatin remodeling complex, is required for IRF4 expression and functionally associates with IRF4 protein on chromatin. Deleting Arid1a in activated murine B cells disrupts IRF4-dependent transcriptional networks and …

Dec 12, 2022 · Ablation of the ARID1A promotes the differentiation of MP subset both in MYC low and MYC high cells, indicating that cBAF likely functions downstream of MYC to co-opt T-cell fate decisions....

Jul 8, 2024 · ARID1A, a member of the SWI/SNF chromatin remodeling complex, is required for IRF4 expression and functionally associates with IRF4 protein on chromatin. Deleting Arid1a in activated murine B cells disrupts IRF4-dependent transcriptional networks and …

Nov 11, 2017 · ARID1A, a SWI/SNF chromatin remodeling gene, is commonly mutated in cancer and hypothesized to be tumor suppressive. In some hepatocellular carcinoma patients, ARID1A was highly expressed in primary tumors but not in metastatic lesions, suggesting that ARID1A can be lost after initiation.

Mechanistic studies revealed that ARID1A blocked the interaction between cyclin-dependent kinases (CDKs) and retinoblastoma protein (Rb), reducing the phosphorylation of Rb. Dephosphorylated Rb suppressed E2F1 activity and then suppressed cancer stemness by inactivating c-Myc.

In this review, we discuss the spectrum of ARID1A alterations in cancers, tumor suppression mechanisms of ARID1A, oncogenic pathways cooperating with ARID1A, and clinical implications of ARID1A mutation.

Aug 28, 2021 · ARID1A mutations were associated with a poorer prognosis in HCC patients. The mRNA level of MYC was significantly higher in patients with an ARID1A mutation compared to those without a mutation. Ectopic expression of ARID1A inhibited HCC cell proliferation.